ISPOR Real-World Evidence Summit 2024

The Summit will cover the latest developments in the use of real-world evidence across the regulatory-HTA-payer decision-making continuum with a focus on methods, data transportability, and infrastructure.

Topics to be covered include causal inference and external control arms for comparative effectiveness analyses, the hierarchy of RWE studies, and the role of patient registries. The use of RWE in Joint Clinical Assessment of the EU HTA regulation will be explored, also with insights from the cross-border collaborations on pricing and reimbursement in the EU countries. Finally, feasibility of HTA reassessment post market entry will be considered, drawing from lessons learned from US Medicare Drug Price Negotiation.

The Summit is a co-located event at ISPOR Europe 2024.